Merck's SAC-TMT Phase 3 Shows Improved Survival in Endometrial Cancer at ESMO
MRK sits 79% above its 52-week low of $82.01.
Summary
Merck presented first-time pivotal Phase 3 data at ESMO 2026, including SAC-TMT showing improved survival in endometrial cancer. This is the first disclosure of these results, adding a new oncology asset to the pipeline. The data could support future regulatory filings and expand Merck's oncology franchise beyond Keytruda. No specific numbers were provided in the headline, but the survival improvement is a clinically meaningful endpoint. Merck will present first Phase 3 INTerpath-001 data on mRNA-4157 plus KEYTRUDA in resected stage IIB–IV melanoma at an ESMO Presidential Symposium.
Updated with a Wiseek News report · What changed
Updates
· Wiseek News — Merck will present first Phase 3 INTerpath-001 data on mRNA-4157 plus KEYTRUDA in resected stage IIB–IV melanoma at an ESMO Presidential Symposium.
At the time of this announcement, MRK was trading at $146.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $358.9B. The 52-week trading range was $82.01 to $156.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.